Indrayani Biotech Ltd
Indrayani Biotech Ltd (INDRANIB) last reported results for the quarter ended Mar 2026, with sales of ₹37.76 crore and net profit of ₹0.98 crore. The stock last traded at ₹10.2, a market capitalisation of ₹79.6 crore, on a P/E of 36.9. Over the past 52 weeks the stock has ranged between ₹6.69 and ₹18. Figures are as of 6 Oct 2026 and are not real time.
Indrayani Biotech Ltd share price and key metrics
- Current price
- ₹10.2
- Market cap
- ₹79.6 cr
- Stock P/E
- 36.9
- Book value
- ₹9.33
- ROE
- 2.97%
- ROCE
- 4.24%
- Dividend yield
- 0.00%
- 52w high / low
- 18.0/6.69
Metrics as of 6 Oct 2026. Not real time.
Track Indrayani Biotech Ltd
Cruxal reads every Indrayani Biotech Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Indrayani Biotech Ltd growth and returns
- 10 Years
- %
- 5 Years
- 46%
- 3 Years
- -5%
- TTM
- 6%
- 10 Years
- %
- 5 Years
- 18%
- 3 Years
- -38%
- TTM
- 135%
- 10 Years
- 3%
- 5 Years
- -20%
- 3 Years
- -46%
- 1 Year
- -27%
- 10 Years
- %
- 5 Years
- 6%
- 3 Years
- 1%
- Last Year
- 3%
Indrayani Biotech Ltd quarterly results
In the quarter ended Mar 2026, sales were ₹37.76 cr, down 25.3% from ₹50.57 cr a year earlier. Net profit turned positive at ₹0.98 cr.
| ₹ crore | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 31.53 | 30.81 | 17.32 | 50.57 | 29.1 | 35.95 | 35.01 | 37.76 |
| Expenses | 25.55 | 25.7 | 14.4 | 56.31 | 26.92 | 33.5 | 32.22 | 35.54 |
| Operating profit | 5.98 | 5.11 | 2.92 | -5.74 | 2.18 | 2.45 | 2.79 | 2.22 |
| OPM % | 18.97% | 16.59% | 16.86% | -11.35% | 7.49% | 6.82% | 7.97% | 5.88% |
| Other income | 0.04 | 0.3 | 0 | 2.78 | 1.06 | 1.8 | 0.83 | 0.88 |
| Interest | 0.83 | 1.42 | 1.03 | 7.07 | 2.17 | 1.89 | 2.47 | 3.08 |
| Depreciation | 4.25 | 2.79 | 1.46 | -1.72 | 0.86 | 1.3 | 1.01 | 1.13 |
| Profit before tax | 0.94 | 1.2 | 0.43 | -8.31 | 0.21 | 1.06 | 0.14 | -1.11 |
| Tax % | 9.57% | -1.67% | 18.60% | 2.53% | 23.81% | 14.15% | 21.43% | -187.39% |
| Net profit | 0.85 | 1.22 | 0.35 | -8.53 | 0.16 | 0.91 | 0.12 | 0.98 |
| EPS (₹) | 0.11 | 0.16 | 0.03 | -1.09 | 0.02 | 0.05 | 0.02 | 0.13 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Indrayani Biotech Ltd annual results
| ₹ crore | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 39 | 58 | 50 | 21 | 61 | 163 | 165 | 130 | 138 |
| Operating profit | -0 | 1 | 1 | 3 | -5 | 7 | 17 | 24 | 6 | 10 |
| OPM % | -105% | 1.9% | 0.9% | 6% | -24% | 11% | 11% | 14% | 4.9% | 7% |
| Net profit | -0 | -0 | -0 | 1 | -11 | 4 | 12 | 10 | -6 | 2 |
| EPS (₹) | — | -0.08 | -0.10 | 1.31 | -1.91 | 0.76 | 1.49 | 0.81 | -0.78 | 0.28 |
TTM is the trailing twelve months to the most recent quarter.
Indrayani Biotech Ltd balance sheet
| ₹ crore | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 6 | 4 | 4 | 4 | 34 | 34 | 34 | 46 | 46 | 46 |
| Reserves | -6 | -0 | -0 | 27 | -15 | -10 | 12 | 22 | 27 | 27 |
| Borrowings | 0 | 0 | 0 | 14 | 16 | 19 | 79 | 113 | 137 | 128 |
| Other liabilities | 1 | 6 | 9 | 7 | 5 | 8 | 31 | 54 | 58 | 52 |
| Total liabilities | 1 | 10 | 12 | 51 | 40 | 51 | 156 | 234 | 268 | 253 |
| Fixed assets | 1 | 6 | 6 | 17 | 15 | 17 | 57 | 62 | 58 | 60 |
| CWIP | -0 | 0 | 0 | 14 | 14 | 13 | 14 | 20 | 26 | 27 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 0 | 4 | 7 | 21 | 11 | 22 | 85 | 151 | 184 | 166 |
| Total assets | 1 | 10 | 12 | 51 | 40 | 51 | 156 | 234 | 268 | 253 |
As reported by the company. Total assets equal total liabilities by construction.
Indrayani Biotech Ltd cash flow
| ₹ crore | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1 | 2 | 6 | 0 | 4 | 16 | -30 | -7 | 32 |
| Cash from investing | -3 | -0 | -4 | -1 | -1 | -47 | -16 | 25 | -13 |
| Cash from financing | 2 | -1 | -1 | -0 | -3 | 33 | 44 | -18 | -15 |
| Net cash flow | 0 | 1 | 1 | -1 | 1 | 2 | -2 | -0 | 4 |
| Free cash flow | -2 | 2 | 2 | -0 | 3 | -25 | -47 | -8 | 23 |
| CFO / operating profit | 122% | 331% | 215% | -5% | 61% | 94% | -128% | -124% | 328% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Indrayani Biotech Ltd operating ratios
| Per year | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 28% | 12% | — | -13% | 16% | 23% | 14% | 3% | 4% |
| Debtor days | 0 | 26 | 26 | 52 | 84 | 84 | 67 | 87 | 165 | 155 |
| Inventory days | 365 | — | — | 57 | 25 | 14 | 44 | 159 | 182 | 147 |
| Days payable | 365 | — | — | 70 | 77 | 52 | 81 | 141 | 104 | 55 |
| Cash conversion cycle | 0 | 26 | 26 | 38 | 32 | 46 | 30 | 106 | 243 | 247 |
| Working capital days | -1,883 | -22 | -19 | 30 | -59 | -12 | 6 | 127 | 211 | 163 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Indrayani Biotech Ltd shareholding pattern
Promoters held 32.92% at Jun 2026, broadly unchanged since Jun 2025. DIIs 3.13%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 33.40% | 33.28% | 33.28% | 33.28% | 33.26% | 33.26% | 33.26% | 32.92% |
| DIIs | 5.59% | 5.25% | 3.66% | 3.11% | 3.13% | 3.13% | 3.13% | 3.13% |
| Public | 61.01% | 61.49% | 63.07% | 63.62% | 63.61% | 63.61% | 63.62% | 63.94% |
| No. of shareholders | 24,419 | 25,254 | 25,126 | 25,704 | 25,686 | 25,565 | 25,509 | 25,811 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Indrayani Biotech Ltd corporate filings
- Compliance Certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulation 2018, for the quarter ended 30th September 2026.Company Updatelow impact
- Indrayani Biotech reports mixed quarterly financial results with notable revenue growth but fluctuating profitability, and announces a strategic reorganization of its board committees.Board Meetingmedium impact
Cruxal's analysis: Indrayani Biotech's latest quarterly results show revenue of approximately ₹41.53 crore…
Read the full analysis - Indrayani Biotech Ltd announces sale of subsidiary shares under Regulation 30 of SEBI LODR 2015Company Updatelow impact
Cruxal's analysis: On September 30, 2026, Indrayani Biotech Ltd disclosed the sale of shares of its…
Read the full analysis - Indrayani Biotech to hold Board Meeting on 7th October 2026 to consider Q1 FY2027 unaudited financial resultsBoard Meetinglow impact
Cruxal's analysis: Indrayani Biotech Limited has announced a Board meeting scheduled for 7th October 2026 to…
Read the full analysis - Intimation of Closure of Trading Window for the Quarter and Half year Ending 30th September, 2026Insider Trading / SASTlow impact
- Indrayani Biotech Limited Announces Rights Issue of 32.53 lakh Equity Shares to Raise 48.79 croreCompany Updatehigh impact
Cruxal's analysis: Indrayani Biotech Limited has announced a Rights Issue of 32.53 lakh fully paid-up equity…
Read the full analysis - Indrayani Biotech Limited Announces Rights Issue of up to 3.25 crore Equity Shares to Raise 48.79 croreCompany Updatehigh impact
Cruxal's analysis: Indrayani Biotech Limited has announced a rights issue of up to 3,25,25,897 partly…
Read the full analysis - Indrayani Biotech Limited Announces Revised Schedule for Partly Paid-up Rights IssueCorp. Actionmedium impact
Cruxal's analysis: Indrayani Biotech Limited has officially rescheduled its partly paid-up rights issue…
Read the full analysis - Indrayani Biotech Limited Appoints New Company Secretary and Compliance OfficerCompany Updatelow impact
Cruxal's analysis: Indrayani Biotech Limited has announced the appointment of Mr. C.S. Shanmuga Sundar as…
Read the full analysis - Indrayani Biotech Limited Announces Resignation of Secretarial AuditorCompany Updatelow impact
Cruxal's analysis: Indrayani Biotech Limited has formally disclosed the resignation of its Secretarial…
Read the full analysis - Indrayani Biotech Limited Secures ROC Extension for AGM to Facilitate Capital Restructuring and Rights IssueCompany Updatemedium impact
Cruxal's analysis: Indrayani Biotech Limited has received approval from the Registrar of Companies (ROC)…
Read the full analysis - Indrayani Biotech Limited Announces Audited Financial Results for Quarter and Year Ended March 31, 2026Company Updatelow impact
Cruxal's analysis: Indrayani Biotech Limited has published its audited standalone and consolidated financial…
Read the full analysis - Indrayani Biotech Limited Reports Audited FY26 Financials with Qualified Audit OpinionCompany Updatemedium impact
Cruxal's analysis: Indrayani Biotech Limited reported consolidated revenue of 137.83 crore for FY26…
Read the full analysis - Indrayani Biotech Limited Reports Audited FY26 Financial Results with Qualified OpinionResulthigh impact
Cruxal's analysis: Indrayani Biotech Limited has released its audited standalone and consolidated financial…
Read the full analysis - Indrayani Biotech Limited schedules Board Meeting for August 17, 2026, to approve audited financial results for the year ended March 31, 2026Board Meetinglow impact
Cruxal's analysis: Indrayani Biotech Limited has issued a formal intimation under SEBI Regulation 29…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.